Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors
Status:
Terminated
Trial end date:
1997-01-03
Target enrollment:
Participant gender:
Summary
Current therapies for Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors
provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston
therapy suggest that it may prove beneficial in the treatment of Metastatic, Recurrent, or
Refractory Primitive Neuroectodermal Tumors.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Metastatic, Recurrent, or Refractory Primitive
Neuroectodermal Tumors.